Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.

MLA

Maruyama, Dai, et al. “Valemetostat Monotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human, Multicentre, Open-Label, Single-Arm, Phase 1 Study.” The Lancet. Oncology, Oct. 2024. EBSCOhost, https://doi.org/10.1016/S1470-2045(24)00502-3.

APA

Maruyama, D., Jacobsen, E., Porcu, P., Allen, P., Ishitsuka, K., Kusumoto, S., Narita, T., Tobinai, K., Foss, F., Tsukasaki, K., Feldman, T., Imaizumi, Y., Izutsu, K., Morishima, S., Yamauchi, N., Yuda, J., Brammer, J. E., Kawamata, T., Ruan, J., … Horwitz, S. M. (2024). Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. The Lancet. Oncology. https://doi.org/10.1016/S1470-2045(24)00502-3

Chicago

Maruyama, Dai, Eric Jacobsen, Pierluigi Porcu, Pamela Allen, Kenji Ishitsuka, Shigeru Kusumoto, Tomoko Narita, et al. 2024. “Valemetostat Monotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human, Multicentre, Open-Label, Single-Arm, Phase 1 Study.” The Lancet. Oncology, October. doi:10.1016/S1470-2045(24)00502-3.